Investments
27Portfolio Exits
4Funds
4Partners & Customers
6About Imperial Innovations
Imperial Innovations is the technology transfer office for Imperial College London that supports Imperial scientists to commercialize their novel technologies through licensing or company formation. Imperial Innovations is an IP Group plc company.

Want to inform investors similar to Imperial Innovations about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Imperial Innovations News
Nov 16, 2020
• Mon, August 24th, 2015 Wikimedia and Tim1965; Logo courtesy of Orthonika Medicine and engineering have come together again at Imperial Innovations, a UK entity focused on commercializing innovative technologies. They have just launched Orthonika, a spinout company from Imperial College London that is working on the creation of a new knee meniscus replacement. According to the August 3, 2015 news release, “A team of Imperial scientists, led by Professors Andrew Amis (Mechanical Engineering) and Justin Cobb (Surgery & Cancer) have collaborated with Sierra MedTech to design a full substitution system for the knee meniscus. To do this, the scientists studied the structure and function of healthy menisci and applied unique manufacturing technologies to replicate the native structure and organisation of the tissue.” Professors Amis and Cobb will sit on the company’s Board of Directors, alongside Mario Alberto Accardi, Ph.D., Massimiliano Graziosi and Dominique Kleyn from Sierra MedTech, and Tom Buckland from Imperial Innovations. Professor Andrew Amis, co-founder of Orthonika, said in the August 3, 2015 news release “The meniscus has an extremely complex structure and is subject to high stresses. It needs to be both elastic and strong, capable of adapting to an individual’s movement. Our team has studied the structure of a natural meniscus and how it reacts to different forces to design a substitute that would function like a natural meniscus. We have also designed a surgical insertion procedure and related instruments, such as a secure means of fixation to the bone. Commenting on the "unique manufacturing technologies to replicate the native structure and organisation of the tissue, ” Dr. Accardi told OTW, “Orthonika uses state of the art manufacturing capabilities that replicate the three-dimensional organisation and mechanics of native meniscus tissue. Specifically, Orthonika utilises a highly engineered, fibre reinforced design to mimic the complex anisotropic arrangement present within the tissue. By incorporating a fibre reinforced approach, Orthonika aims to manufacture a synthetic meniscus replacement product that mimics the complex mechanical properties of the tissue. Combining this manufacturing capability with the innovative research and experimentation undertaken at Imperial College London, the team has characterised the relationship between meniscus mechanical behaviour and the underlying structure and attachment mechanisms.” “Within the next year, Orthonika will finalise designs for the artificial meniscus and plan for a large animal trial to evaluate device performance in vivo. We are extremely excited about the potential for our technology to provide patients with an alternative solution to traditional meniscus repair strategies and look forward to making formidable progress to move our device closer to the clinic.” The news release stated, “Orthonika is a collaboration with Sierra MedTech, a specialist in the design and fabrication of engineered substrates for use in medicine. Orthonika has been launched through Co.Create, the company formation unit of Imperial Innovations.”
Imperial Innovations Investments
27 Investments
Imperial Innovations has made 27 investments. Their latest investment was in Precision Ocular as part of their Series A on February 2, 2016.

Imperial Innovations Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
2/22/2016 | Series A | Precision Ocular | $23.43M | Yes | Consort Medical, Hovione, Imperial Innovations, Neomed Management, Undisclosed Investors, and V-Bio Ventures | 3 |
1/12/2016 | Series A | Import.io | $13M | Yes | 2 | |
8/6/2015 | Seed | Concirrus | $4.65M | Yes | 2 | |
9/1/2010 | Seed VC | |||||
8/25/2010 | Seed VC |
Date | 2/22/2016 | 1/12/2016 | 8/6/2015 | 9/1/2010 | 8/25/2010 |
---|---|---|---|---|---|
Round | Series A | Series A | Seed | Seed VC | Seed VC |
Company | Precision Ocular | Import.io | Concirrus | ||
Amount | $23.43M | $13M | $4.65M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | Consort Medical, Hovione, Imperial Innovations, Neomed Management, Undisclosed Investors, and V-Bio Ventures | ||||
Sources | 3 | 2 | 2 |
Imperial Innovations Portfolio Exits
4 Portfolio Exits
Imperial Innovations has 4 portfolio exits. Their latest portfolio exit was Import.io on January 18, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
1/18/2023 | Acq - Fin | 1 | |||
Date | 1/18/2023 | |||
---|---|---|---|---|
Exit | Acq - Fin | |||
Companies | ||||
Valuation | ||||
Acquirer | ||||
Sources | 1 |
Imperial Innovations Fund History
4 Fund Histories
Imperial Innovations has 4 funds, including Imperial Innovations Innovation Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
Imperial Innovations Innovation Fund | UNKNOWN | Open | 1 | ||
Apollo Therapeutics Fund | |||||
Low Carbon Seed Fund | |||||
University Challenge Seed Fund |
Closing Date | ||||
---|---|---|---|---|
Fund | Imperial Innovations Innovation Fund | Apollo Therapeutics Fund | Low Carbon Seed Fund | University Challenge Seed Fund |
Fund Type | UNKNOWN | |||
Status | Open | |||
Amount | ||||
Sources | 1 |
Imperial Innovations Partners & Customers
6 Partners and customers
Imperial Innovations has 6 strategic partners and customers. Imperial Innovations recently partnered with Oxford BioMedica, Boehringer Ingelheim, and Cystic Fibrosis Gene Therapy Consortium on March 3, 2019.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
3/14/2019 | Partner | United Kingdom, and Germany | Oxford BioMedica : Preliminary Results In our third partnership agreement of the year , we established a collaboration with the UK Cystic Fibrosis Gene Therapy Consortium , Boehringer Ingelheim and Imperial Innovations to develop a novel inhaled gene therapy for cystic fibrosis . | 1 | |
10/1/2018 | Partner | ||||
8/6/2018 | Partner | ||||
8/6/2018 | Partner | ||||
4/12/2016 | Partner |
Date | 3/14/2019 | 10/1/2018 | 8/6/2018 | 8/6/2018 | 4/12/2016 |
---|---|---|---|---|---|
Type | Partner | Partner | Partner | Partner | Partner |
Business Partner | |||||
Country | United Kingdom, and Germany | ||||
News Snippet | Oxford BioMedica : Preliminary Results In our third partnership agreement of the year , we established a collaboration with the UK Cystic Fibrosis Gene Therapy Consortium , Boehringer Ingelheim and Imperial Innovations to develop a novel inhaled gene therapy for cystic fibrosis . | ||||
Sources | 1 |
Imperial Innovations Team
5 Team Members
Imperial Innovations has 5 team members, including current Managing Director, Tony Hickson.
Name | Work History | Title | Status |
---|---|---|---|
Tony Hickson | Managing Director | Current | |
Name | Tony Hickson | ||||
---|---|---|---|---|---|
Work History | |||||
Title | Managing Director | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.